Cost Change Proposal Insufficient To Change Draft Recommendation By NICE On Everolimus For Advanced Renal Cell Carcinoma

Links shared publicly online about this topic.

  • 691
    total visits

Cost Change Proposal Insufficient To Change Draft Recommendation By NICE On Everolimus For Advanced Renal Cell Carcinoma

medicalnewstoday.com —

In its latest draft guidance, NICE has been unable to recommend everolimus (Afinitor, Novartis) for the second line treatment of advanced renal cell carcinoma because it does not provide enough be

View full resource at medicalnewstoday.com

Tags: Cancer, Kidney Cancer Medication, Renal Cell Carcinoma, Kidney Health, Urinary System, Afinitor, Novartis

  • Share

Most Recently Shared on November 29, 2010 at 6:05 pm By:

mnt_cancer MNT Cancer News

Cost Change Proposal Insufficient To Change Draft Recommendation By NICE On Everolimus For Advanced Renal Cell Carcinoma http://mnt.to/3Nfs

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Urology MNT Urology

Advertisement